GlaxoSmithKline: Hypertension, Pulmonary trials
The registry lists 13 Hypertension, Pulmonary studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 3Phase 2 4Phase 3 2Phase 4 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult ParticipantsCompletedNCT04095286Phase 1Results posted
- A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT03177603Phase 2Results posted
- A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy SubjectsCompletedNCT02688387Phase 1Results posted
- Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) PatientsCompletedNCT02551653Phase 1Results posted
- Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)CompletedNCT01462565Phase 4Results posted
- Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529CompletedNCT01342952Phase 2Results posted
- Efficacy and Safety of Ambrisentan in Children 8-18yrsTerminatedNCT01332331Phase 2Results posted
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT01178073Phase 3Results posted
- A Study to Evaluate GSK1325760A - a Long-Term Extension StudyCompletedNCT00554619Phase 3Results posted
- Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial HypertensionCompletedNCT00540436Phase 2Results posted
- Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) SubjectsCompletedNCT03304548
- Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)CompletedNCT01406327
- An Observational Study For AmbrisentanCompletedNCT00679224